Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00335166
Status:
COMPLETED
Last Update Posted:
2008-04-03
First Post:
2006-06-08
Brief Title:
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
Sponsor:
Solvay Pharmaceuticals
Organization:
Solvay Pharmaceuticals
Study Overview
Official Title:
A Multicenter Randomized Double Blind Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter randomized double blind parallel group study of 6 months treatment with SLV308 as monotherapy in patients with early stage PD An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Not requested yet | None | None | None |